Insight Molecular Diagnostics Inc.
IMDXNASDAQHealthcareMedical - Diagnostics & Research
Regular session
$4.28
−$0.06 · -1.38%
IMDX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
38
Expensive
Momentum
31
Weakening
Sentiment
44
Mixed
Risk resilience
29
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteOncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Joshua Riggs
- Listed since
- Dec 30, 2015
- Employees
- 57
Market position
Day range
Current $4.28
52-week range
Current $4.28
- Open
- $4.37
- Previous close
- $4.34
- Volume
- 8.5K
- 0.03× average
- Average volume
- 304.75K
- Average daily volume
- Market cap
- 138.2M USD
- Beta
- 1.82
- Market reference 1
- 50-day average
- $4.9372
- -13.31% below average
- 200-day average
- $5.3885
- -20.57% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 220.48M USD
- P/E (TTM)
- -2.82×
- P/B (TTM)
- -7.38×
- P/S (TTM)
- 82.76×
- EV / EBITDA
- -4.6×
- Earnings yield
- -21.97%
- Free cash flow yield
- -11.10%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 11.17%
- Operating margin
- -2558.74%
- Net margin
- -2955.63%
- Return on equity
- 159.62%
- Return on assets
- -194.99%
- Return on invested capital
- -197.43%
Financial health
- Debt / equity
- -0.12×
- Current ratio
- 1.27×
IMDX peers
ETFs holding IMDX
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 2.21M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $376.87-0.36%
Vanguard Extended Market ETFVXF- Market value
- 1.15M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $244.02-0.62%
iShares Micro-Cap ETFIWC- Market value
- 190.2K
- Weight
- 0.01%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $196.44-0.85%
Continue in GoAI
Research IMDXresearch.disclaimer